Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-10-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
前次募集资金鉴证报告
Regulatory Filings
2019-10-20 Chinese
独立董事关于昆药集团九届十五次董事会相关事项的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent opinion from independent directors regarding specific matters related to guarantees provided by subsidiaries and a special report on the use of previously raised funds. It includes compliance statements with company bylaws, listing rules, and regulatory requirements. The document is relatively short (1010 characters) and focuses on opinions about specific financial guarantees and a special report on fundraising usage, rather than presenting full financial statements or comprehensive financial performance data. It does not contain quarterly or annual financial results, nor is it a transcript, presentation, or announcement of voting results. The content aligns with an Audit Report / Information type, as it provides independent opinions on specific financial and compliance matters, including a special report on fundraising usage, which is typical for audit-related disclosures. Therefore, the most appropriate classification is Audit Report / Information (AR). Q3 2019
2019-10-20 Chinese
九届九次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kunming Pharmaceutical Group Co., Ltd. It includes voting results on various proposals such as guarantees for bank credit lines, a revised special report on the use of previously raised funds, and approval of the company's 2019 third quarter report. The document contains no actual financial statements or detailed financial data but rather the Supervisory Board's opinions and approvals of reports and proposals. It is a formal announcement of board decisions and approvals, not the financial report itself. The document length is short (1922 characters), and it serves as a formal announcement of resolutions and approvals rather than the full quarterly report. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management approvals.
2019-10-20 Chinese
关于子公司昆药集团医药商业有限公司为曲靖市康桥医药有限责任公司提供2,400万元银行综合授信额度担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a guarantee provided by a subsidiary company for a bank credit facility to another company. It includes details about the guarantee amount, the parties involved, internal decision procedures, financial data of the guaranteed company, and board opinions. The document is relatively short (1966 characters) and does not contain comprehensive financial statements or detailed financial performance data. It is a regulatory announcement about a financing guarantee, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes.
2019-10-20 Chinese
九届十五次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 15th meeting of the 9th board, including approvals of guarantees, establishment of subsidiaries, share acquisitions, resignation of a vice president, and approval of a third quarter report agenda. The document includes voting results and references to other announcements but does not contain full financial statements or detailed financial analysis itself. It is primarily a formal announcement of board decisions and management changes, not a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1985 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2019-10-20 Chinese
关于子公司昆药集团医药商业有限公司在昭通市设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group about the establishment of a wholly-owned subsidiary by its subsidiary in Zhaotong City. It details the investment amount, business scope, and risk analysis related to this new subsidiary. The document is a formal announcement of a corporate action (setting up a new subsidiary) and does not contain financial statements, audit information, or detailed financial performance data. It is not a report, earnings release, or management discussion. It is also not related to board changes, voting results, or legal proceedings. The content fits best with a Capital/Financing Update (CAP) as it concerns investment and capital allocation activities by the company.
2019-10-20 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.